Cogent Biosciences, Inc. (COGT) Q3 FY2026 earnings

Reported results

• Net loss was $111.4 million for the third quarter of 2026 compared to a net loss of $80.9 million for the third quarter of 2025.
• Research and development expenses were $75.1 million for the third quarter of 2026 compared to $69.0 million for the third quarter of 2025.
• General and administrative expenses were $42.1 million for the third quarter of 2026 compared to $14.4 million for the third quarter of 2025.
• Cash, cash equivalents and marketable securities were $791.1 million as of September 30, 2026, compared to $792.3 million as of June 30, 2026.
• Research and development expenses included non-cash stock compensation expense of $7.5 million for the third quarter of 2026 compared to $5.4 million for the third quarter of 2025.
• General and administrative expenses included non-cash stock compensation expense of $9.4 million for the third quarter of 2026 compared to $5.2 million for the third quarter of 2025.

Guidance

• The company believes that its cash, cash equivalents and marketable securities will be sufficient to fund its operating expenses and capital expenditure requirements into late 2028.

Price and volatility reaction

The stock moved +7.0% on the print. No front-expiry chain was on file, so there is no straddle expected move. 30-day ATM implied volatility moved -1.6 vol points across the event (constant-maturity series — not the front-week crush).

Source

The figures above come from the earnings release the company filed with the SEC on 2026-11-05 (8-K, Item 2.02). Read the original filing on sec.gov.